Efficacy News and Research

RSS

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

A technology whose roots date to the 1800s has the potential to offer an extraordinary new advantage to modern-day medicine.

9 Jul 2015

UK study suggests new approach to develop highly-potent drugs

A new study led by University of Kentucky researchers suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.

9 Jul 2015

Internet-based program can help people manage their chronic pain, reduce reliance on opioids

Washington State University researchers have found that people can manage chronic pain and reduce their reliance on opioids through an Internet-based program that teaches non-medical alternatives like increased physical activity, thinking more positively and dealing with emotions.

8 Jul 2015

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.

8 Jul 2015

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the independent Data Safety Monitoring Board recommends the continuation, per protocol, of its phase 2 clinical trial of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.

8 Jul 2015

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

Xiaoting Zhang, PhD, associate professor in the Department of Cancer Biology at the University of Cincinnati College of Medicine, has received a $1.8 million, five-year, R01 award (R01CA197865) from the National Cancer Institute to continue breast cancer research focusing on the function of the protein MED1 on HER2-positive breast cancer.

8 Jul 2015

MGH-CEM researchers develop microfabricated device to analyze effects of pro-drugs on cancer cells

A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine has developed a novel approach that dramatically simplifies the evaluation of the liver's drug-metabolizing activity and the potential toxic effects of the products of that activity on other organs.

8 Jul 2015

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin citicoline (Jarrow Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence. The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin citicoline or placebo add-on therapy for 12 weeks.

7 Jul 2015

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

7 Jul 2015

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.

7 Jul 2015

Allergan enters into agreement to acquire Oculeve

Allergan plc, a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction.

6 Jul 2015

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Sylvia Hernando became a Community Health Worker (CHW) because she wanted to help others. Hernando had been a stay-at-home mother and was looking to go back to school when she heard about the CHW certification program at The University of Texas Health Science Center at Houston School of Public Health.

6 Jul 2015

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

Redwood Pharma AB has entered into a licensing agreement with Broda Technologies Co., Ltd., operating in both the US and China, to use the company's proprietary IntelliGel supramolecular hydrogel technology in its lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies.

3 Jul 2015

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative colitis (UC).

3 Jul 2015

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

3 Jul 2015

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

3 Jul 2015

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

A novel synthetic hormone that makes certain skin cells produce more melanin significantly increases pain-free sun exposure in people with erythropoietic protoporphyria, a rare, genetic disorder resulting in excruciating pain within minutes of sun exposure.

3 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma, a global healthcare company focused on skin health, announced today that it has received U.S. Food and Drug Administration approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21.

2 Jul 2015

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.

2 Jul 2015

Efficacy News and Research

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

UK study suggests new approach to develop highly-potent drugs

Internet-based program can help people manage their chronic pain, reduce reliance on opioids

Galmed signs License Agreement for development of blood-based companion diagnostic tool

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

MGH-CEM researchers develop microfabricated device to analyze effects of pro-drugs on cancer cells

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Allergan enters into agreement to acquire Oculeve

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News